Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Polycab India block deal : Promoters likely to sell 0.8% stake worth Rs 887 crore on Thursday : Report
24/09/2025
Akzo Nobel India block deals : Promoter offloads Rs 765 crore stake ; Nippon, Goldman, Citi among buyers
24/09/2025
Rich Dad Poor Dad author Robert Kiyosaki-inspired portfolio surges 40% in 2025 as gold, silver and Bitcoin rally
24/09/2025
Sebi raises net worth requirement for custodians to Rs 75 cr
24/09/2025
Midcap Momentum : 7 stocks reporting rising EPS for 4 consecutive quarters
24/09/2025
Investors' hunt for Groww unlisted shares at steep $9 billion valuation raises eyebrows. What does it tell about IPO (...)
24/09/2025
